患有De Novo转移性化敏感前列腺癌的老年男性:治疗和并发症是否重要
Ugur Ozberk1, Selin Akturk Esen1, Alican Uguz1
1Department of Medical Oncology, Ankara City Hospital, 06800 Ankara, Türkiye.
Medicina (Kaunas, Lithuania)
|November 27, 2025
概括
患有新发转移性割敏感前列腺癌 (mCSPC) 的老年男性经常患有侵袭性疾病. 恩扎胺在数值上显示了更长的存活时间,并且没有高血压可能会降低这一群体的进展风险.
科学领域:
- 在瘤学瘤学.
- 老年医学 老年医学
- 临床泌尿病学 临床泌尿病学
背景情况:
- 前列腺癌 (PC) 主要影响老年男性,新发转移性呈现越来越多.
- 老年患者在临床试验中代表性不足,限制了治疗的适用性.
- 在老年人中,新发的转移性割敏感前列腺癌 (mCSPC) 需要具体的临床表征.
研究的目的:
- 描述老年患者 (≥75岁) 的临床特征,治疗模式和生存结果. de novo mCSPC.
- 为了评估治疗有效性和预后因素在这个未经研究的人群.
主要方法:
- 追溯分析90名年龄≥75岁的患者,新出现的mCSPC.
- 收集了关于临床特征,接受的治疗,无进展生存期 (PFS) 和总生存期 (OS) 的数据.
- 统计分析以确定与进展和生存相关的因素.
主要成果:
- 平均年龄为81岁;大多数患者患有高体积疾病和高度瘤 (Gleason 9-10).
- 许多患者接受的治疗强度低于推的治疗 (单独或与双胺一起接受雄激素剥夺疗法 (ADT)).
- 恩扎胺与数值较长的PFS (25.4个月) 和OS (30.5个月) 相关,但在统计学上没有显著意义.
- 没有高血压与更低的进展风险有关 (HR 0.46,p=0.028).
结论:
- 患有 de novo mCSPC 的老年患者经常出现侵袭性疾病.
- 恩扎胺在这个队列中显示出改善生存结果的趋势.
- 诸如高血压之类的并发症可能会影响进展风险,这凸显了老年男性mCSPC患者个性化治疗策略的必要性.
相关概念视频
Disorders of the Male Reproductive System
3.9K
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
3.9K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Pharmacodynamics in Geriatric Patients: Effects of Age
180
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
180
Drug Dosing: Geriatric Patients
214
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
214
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K


